6 results on '"Bakkum-Gamez, Jamie N."'
Search Results
2. The cost of diagnosing endometrial cancer: Quantifying the healthcare cost of an abnormal uterine bleeding workup.
- Author
-
Warring SK, Borah B, Moriarty J, Gullerud R, Lemens MA, Destephano C, Sherman ME, and Bakkum-Gamez JN
- Subjects
- Biopsy economics, Cohort Studies, Electronic Health Records, Endometrial Neoplasms complications, Endometrial Neoplasms pathology, Female, Humans, Middle Aged, Minnesota, Perimenopause, Precancerous Conditions complications, Precancerous Conditions diagnosis, Precancerous Conditions pathology, Prospective Studies, Uterine Hemorrhage etiology, Biopsy statistics & numerical data, Endometrial Neoplasms diagnosis, Health Care Costs
- Abstract
Objective: The evaluation of women with perimenopausal abnormal uterine bleeding (AUB) and postmenopausal bleeding (PMB) to detect endometrial cancer (EC) and its precursors is not standardized and can vary widely. Consequently, costs associated with the workup and management undoubtedly vary. This study aimed to quantify costs of AUB/PMB evaluation to understand the healthcare burden associated with securing a pathologic diagnosis., Methods: Women ≥45 years of age presenting to a single institution gynecology clinic with AUB/PMB for diagnostic workup were prospectively enrolled February 2013-October 2017 for a lower genital tract biospecimen research study. Clinical workup of AUB/PMB was determined by individual provider discretion. Costs of care were collected from administrative billing systems from enrollment to 90 days post enrollment. Costs were standardized and inflation-adjusted to 2017 US Dollars (USD)., Results: In total, there were 1017 women enrolled with 5.6% diagnosed with atypical hyperplasia or endometrial cancer (EC). Within the full cohort, 90-day median cost for AUB/PMB workup and management was $2279 (IQR $512-4828). Among patients with a diagnostic biopsy, median 90-day costs ranged from $2203 (IQR $499-3604) for benign or disordered proliferative endometrium (DPE) diagnosis to $21,039 (IQR $19,084-24,536) for a diagnosis of EC., Conclusions: The costs for diagnostic evaluation of perimenopausal AUB and PMB vary greatly according to ultimate tissue-based diagnosis. Even reassuring benign findings that do not require further intervention-the most common in this study's cohort-yield substantial costs. The development of sensitive, specific, and more cost-effective diagnostic strategies is warranted., Competing Interests: Declaration of Competing Interest Dr. Jamie Bakkum-Gamez was funded as noted above by The V Foundation for Cancer Research (T2016–001-03) and National Cancer Institute (grants P30 CA 15083 and Z01CP010124–21). She is also listed as an inventor on intellectual property owned by Mayo Clinic and licensed to Exact Sciences. Bijan Borah is a consultant for Exact Sciences. Dr. Mark Sherman participates in research on developing an early endometrial cancer detection test, which is partly funded by Exact Sciences., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
3. Using Bundled Interventions to Reduce Surgical Site Infection After Major Gynecologic Cancer Surgery.
- Author
-
Johnson MP, Kim SJ, Langstraat CL, Jain S, Habermann EB, Wentink JE, Grubbs PL, Nehring SA, Weaver AL, McGree ME, Cima RR, Dowdy SC, and Bakkum-Gamez JN
- Subjects
- Evidence-Based Medicine, Female, Humans, Interdisciplinary Communication, Middle Aged, Minnesota, Prospective Studies, Quality Improvement, Genital Neoplasms, Female surgery, Outcome and Process Assessment, Health Care, Patient Care Bundles standards, Surgical Wound Infection prevention & control
- Abstract
Objective: To investigate whether implementing a bundle, defined as a set of evidence-based practices performed collectively, can reduce 30-day surgical site infections., Methods: Baseline surgical site infection rates were determined retrospectively for cases of open uterine cancer, ovarian cancer without bowel resection, and ovarian cancer with bowel resection between January 1, 2010, and December 31, 2012, at an academic center. A perioperative bundle was prospectively implemented during the intervention period (August 1, 2013, to September 30, 2014). Prior established elements were: patient education, 4% chlorhexidine gluconate shower before surgery, antibiotic administration, 2% chlorhexidine gluconate and 70% isopropyl alcohol coverage of incisional area, and cefazolin redosing 3-4 hours after incision. New elements initiated were: sterile closing tray and staff glove change for fascia and skin closure, dressing removal at 24-48 hours, dismissal with 4% chlorhexidine gluconate, and follow-up nursing phone call. Surgical site infection rates were examined using control charts, compared between periods using χ or Fisher exact test, and validated against the American College of Surgeons National Surgical Quality Improvement Program decile ranking., Results: The overall 30-day surgical site infection rate was 38 of 635 (6.0%) among all cases in the preintervention period, with 11 superficial (1.7%), two deep (0.3%), and 25 organ or space infections (3.9%). In the intervention period, the overall rate was 2 of 190 (1.1%), with two organ or space infections (1.1%). Overall, the relative risk reduction in surgical site infection was 82.4% (P=.01). The surgical site infection relative risk reduction was 77.6% among ovarian cancer with bowel resection, 79.3% among ovarian cancer without bowel resection, and 100% among uterine cancer. The American College of Surgeons National Surgical Quality Improvement Program decile ranking improved from the 10th decile to first decile; risk-adjusted odds ratio for surgical site infection decreased from 1.6 (95% confidence interval 1.0-2.6) to 0.6 (0.3-1.1)., Conclusion: Implementation of an evidence-based surgical site infection reduction bundle was associated with substantial reductions in surgical site infection in high-risk cancer procedures.
- Published
- 2016
- Full Text
- View/download PDF
4. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.
- Author
-
Al Hilli MM, Bakkum-Gamez JN, Mariani A, Cliby WA, Mc Gree ME, Weaver AL, Dowdy SC, and Podratz KC
- Subjects
- Aged, Cohort Studies, Disease-Free Survival, Endometrial Neoplasms surgery, Female, Humans, Middle Aged, Minnesota epidemiology, Retrospective Studies, Diabetes Mellitus drug therapy, Diabetes Mellitus epidemiology, Endometrial Neoplasms epidemiology, Hypoglycemic Agents administration & dosage, Metformin administration & dosage
- Abstract
Objective: To examine the influence of diabetes and metformin therapy on overall survival (OS) and progression-free survival (PFS) in patients with endometrial cancer (EC) by using propensity score (PS) matching to account for confounding factors., Methods: We retrospectively identified consecutive patients with stage I-IV EC managed surgically from 1999 through 2008 and stratified patients by diabetes status. PS matching was used to adjust for confounding covariates. OS and PFS were compared between diabetic and nondiabetic matched pairs and between matched pairs of diabetic patients with or without metformin therapy. Cox proportional hazards models were fit to estimate the effects on outcomes., Results: Among 1303 eligible patients (79% stage I, 28% grade 3), 277 (21.3%) had a history of diabetes. Among diabetic patients, treatment consisted of metformin in 116 (41.9%); 57 (20.6%) had other oral agents, 51 (18.4%) insulin with or without other oral agents, and 53 (19.1%) diet modification only. For PS-matched diabetic and nondiabetic patients with EC, OS (hazard ratio [HR], 1.01; 95% CI, 0.72-1.42) and PFS (HR, 1.01; 95% CI, 0.60-1.69) were similar between matched subsets. No differences in OS and PFS were observed when comparing PS-matched metformin users with nondiabetic patients (OS HR, 1.03; 95% CI, 0.57-1.85; PFS HR, 1.14; 95% CI, 0.49-2.62) or with other diabetic patients (OS HR, 0.61; 95% CI, 0.30-1.23; PFS HR, 1.06; 95% CI, 0.34-3.30)., Conclusions: When adjusted for confounding covariates, OS and PFS are similar between diabetic and nondiabetic patients with EC and between metformin users and nonusers or nondiabetic patients., (Copyright © 2015. Published by Elsevier Inc.)
- Published
- 2016
- Full Text
- View/download PDF
5. Risk-adjusted outcomes in elderly endometrial cancer patients: implications of the contrasting impact of age on progression-free and cause-specific survival.
- Author
-
AlHilli MM, Bakkum-Gamez JN, Mariani A, Weaver AL, McGree ME, Keeney GL, Jatoi A, Dowdy SC, and Podratz KC
- Subjects
- Age Factors, Aged, Disease-Free Survival, Endometrial Neoplasms epidemiology, Endometrial Neoplasms pathology, Female, Humans, Logistic Models, Minnesota epidemiology, Neoplasm Staging, Proportional Hazards Models, Survival Rate, Treatment Outcome, United States, Endometrial Neoplasms surgery
- Abstract
Objective: To reexamine the tenet that advanced age independently impacts progression-free and cause-specific survival in patients with endometrial cancer (EC)., Methods: Patients undergoing surgery for stages I-IIIC EC between 1999 and 2008 were stratified by age (<70 vs ≥70years). Three propensity score (PS) methods were utilized to adjust for confounding risk factors. The PS, or conditional probability of being ≥70years old, given a patient's baseline covariates, was derived using logistic regression. The Cox proportional hazards models were fit to estimate the effect of age≥70years on outcomes., Results: Of 1182 eligible patients, 822 (69.5%) were <70 and 360 (30.5%) were ≥70. Patients ≥70 were more likely to have multiple adverse risk factors. The total standardized difference of these factors was reduced by 74% and 81%, respectively, using PS-stratification and PS-matching analyses. The nonsignificant trend toward an association between progression-free survival and age≥70 in an unadjusted analysis (hazard ratio [HR], 1.40; 95% CI, 0.95-2.04) was further attenuated in the 3 PS analyses. The unadjusted HR for the association between age≥70 and cause-specific survival was 2.03 (95% CI, 1.32-3.13). HRs were attenuated in PS analyses but retained significance (except for PS matching), potentially reflecting differences in salvage therapies (P<.001), including a 3-fold greater use of chemotherapy in those <70., Conclusion: When risk-adjusted for the higher prevalence of adverse prognostic factors in elderly EC patients, progression-free survival after primary therapy is not age dependent but the less favorable cause-specific survival in this cohort may reflect age-related postrecurrence treatment differences., (Copyright © 2015 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
6. Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma.
- Author
-
Lessard-Anderson CR, Handlogten KS, Molitor RJ, Dowdy SC, Cliby WA, Weaver AL, Sauver JS, and Bakkum-Gamez JN
- Subjects
- Carcinoma, Ovarian Epithelial, Case-Control Studies, Female, Humans, Middle Aged, Minnesota epidemiology, Risk Factors, Sterilization, Tubal methods, Neoplasms, Glandular and Epithelial epidemiology, Ovarian Neoplasms epidemiology, Peritoneal Neoplasms epidemiology, Sterilization, Tubal statistics & numerical data
- Abstract
Objective: To determine the effect of excisional tubal sterilization on subsequent development of serous epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC)., Methods: We performed a population-based, nested case-control study using the Rochester Epidemiology Project. We identified all patients with a diagnosis of serous EOC or PPC from 1966 through 2009. Each case was age-matched to 2 controls without either diagnosis. Odds ratios (ORs) and corresponding 95% CIs were estimated from conditional logistic regression models. Models were adjusted for prior hysterectomy, prior salpingo-oophorectomy, oral contraceptive use, endometriosis, infertility, gravidity, and parity., Results: In total, we identified 194 cases of serous EOC and PPC during the study period and matched them with 388 controls (mean [SD] age, 61.4 [15.2] years). Fourteen cases (7.2%) and 46 controls (11.9%) had undergone tubal sterilization. Adjusted risk of serous EOC or PPC was slightly lower after any tubal sterilization (OR, 0.59 [95% CI, 0.29-1.17]; P=.13). The rate of excisional tubal sterilization was lower in cases than controls (2.6% vs 6.4%). Adjusted risk of serous EOC and PPC was decreased by 64% after excisional tubal sterilization (OR, 0.36 [95% CI, 0.13-1.02]; P=.054) compared with those without sterilization or with nonexcisional tubal sterilization., Conclusions: We present a population-based investigation of the effects of excisional tubal sterilization on the risk of serous EOC and PPC. Excisional methods may confer greater risk reduction than other sterilization methods., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.